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Pre-post effect sizes should be avoided in
meta-analyses
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Aims The standardised mean difference (SMD) is one of the most used effect sizes to indicate the effects of treatments.
It indicates the difference between a treatment and comparison group after treatment has ended, in terms of standard
deviations. Some meta-analyses, including several highly cited and influential ones, use the pre-post SMD, indicating
the difference between baseline and post-test within one (treatment group).
Methods In this paper, we argue that these pre-post SMDs should be avoided in meta-analyses and we describe the
arguments why pre-post SMDs can result in biased outcomes.
Results One important reason why pre-post SMDs should be avoided is that the scores on baseline and post-test are
not independent of each other. The value for the correlation should be used in the calculation of the SMD, while this
value is typically not known. We used data from an ‘individual patient data’meta-analysis of trials comparing cognitive
behaviour therapy and anti-depressive medication, to show that this problem can lead to considerable errors in the esti-
mation of the SMDs. Another even more important reason why pre-post SMDs should be avoided in meta-analyses is
that they are influenced by natural processes and characteristics of the patients and settings, and these cannot be dis-
cerned from the effects of the intervention. Between-group SMDs are much better because they control for such vari-
ables and these variables only affect the between group SMD when they are related to the effects of the intervention.
Conclusions We conclude that pre-post SMDs should be avoided in meta-analyses as using them probably results in
biased outcomes.
Received 22 July 2016; Accepted 4 October 2016
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Introduction
Meta-analyses have become an indispensable tool to
integrate large, often complex and sometimes conflict-
ing fields of research, and to translate the results of this
research into treatment recommendations, guidelines
and advice for policy measures (Higgins & Green,
2011). The methods for conducting meta-analyses
have been developed into sophisticated standards
and procedures, not in the least thanks to the ground-
breaking work of the Cochrane Collaboration (Higgins
& Green, 2011). Unfortunately, however, not all
meta-analyses use the best available methods.
In this paper, we will focus on meta-analyses that
use a specific type of effect size of included studies,
the so-called pre-post effect size and we will show
why such meta-analyses have a high risk to result in
wrong and biased outcomes. Several meta-analyses
that have received considerable attention in their
field and in the media used this method. One example
is the highly cited paper by Kirsch et al. (2008) in which
they showed that anti-depressant medication (ADM)
has small effects in mild depression and is only clinic-
ally relevant in severe depression. Another example is
a meta-analysis in the Journal of the American Medical
Association, showing that long-term psychodynamic
psychotherapy is effective in the treatment of mental
disorders (Leichsenring & Rabung, 2008). And more
recently a meta-analysis suggested that the effects of
cognitive behaviour therapy for depression have
declined over time (Johnsen & Friborg, 2015).
The effect size, also called the standardised mean
difference (SMD) or Cohen’s d, is one of the most
used ways to express the outcome of an intervention
in biomedical research, next to outcomes based on
dichotomous outcomes like the relative risk and odds
ratio. It is calculated as the difference in means
between a treatment and comparison group, divided
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by the pooled standard deviation of the two means. So
the SMD indicates the difference between the treat-
ment and comparison group after the treatment, or
alternatively, the difference between the change in
the outcome in the treatment group and the change
in the outcome in the comparison group.
However, as indicated, some meta-analyses do not
use this ‘regular’ type of SMD (the between-group
SMD), but prefer to use the pre-post SMD, indicating
the difference between the outcome score before the
intervention (at pre-test) and the score after the inter-
vention (at post-test). So, the pre-post SMD indicates
the improvement within one group, while the
between-group SMD indicates the difference between
two groups (the treatment and comparison group).
The pre-post SMD is problematic for several rea-
sons, which will be detailed further.
Pre-post SMDs do not give reliable information
about treatment effects
The most important reason why pre-post SMDs are
problematic is that it only calculates the change within
one group. That means that the pre-post SMD is
uncontrolled and it is impossible to disentangle
which proportion of the SMD is caused by the inter-
vention and which by natural recovery or other pro-
cesses. This is not so much a problem of the pre-post
SMD in itself, but is caused by the design of the studies
for which the pre-post SMD is calculated.
This uncontrolled feature of the SMD is especially
problematic in situations where natural or spontan-
eous change is large, like in depression. It is well-
known that spontaneous recovery in depression is
very high, with up to 40% of patients recovering
within a few months with or without treatment
(Cuijpers et al. 2014a). If the pre-post SMD of different
studies covers different time spans, then the differ-
ences between the SMDs must be considerable, due
to natural recovery alone. These variations are not
related to the effects of the intervention in any way.
But it is not only spontaneous change that affects the
pre-post SMD. Studies are conducted in different popu-
lations, with varying recruitment strategies, with
diverse inclusion criteria, in various settings, communi-
ties, countries. Moreover, variables related to the treat-
ment such as expectations of the patients or hope to
recover soon can have an impact on the pre-post SMD.
Of course that is also true for between-groupSMDs indi-
cating the difference or change between the intervention
and the comparison group. The important difference
between between-group SMDs and pre-post SMDs is,
however, that in the former both the treatment and the
control group are influenced by these variables. That
means that the pre-post SMD is always influenced by
such variables, while the between-group SMD is only
influenced by such variables if these are related to the
effects of the treatment. For example, the time between
pre-test and post-test is always influencing the pre-post
SMD, but in the between-group SMDboth the treatment
and the control group have the same time to follow-up.
This means that the between-group SMD will only be
influenced by time to follow-up if this is associated
with the effects of the treatment, while the pre-post
SMD is always influenced by that.
The most important consequence of this is that the
size of the pre-post SMDs is not informative about
the effects of the intervention, because it can be influ-
enced by many uncontrolled variables that have noth-
ing to do with the intervention. Another corollary is
that there are typically large differences between pre-
post SMDs across studies, resulting in high levels of
heterogeneity. Heterogeneity refers to the variability
in the effect sizes that are found for included studies
in a meta-analysis. If there is significant heterogeneity,
it means that the observed effect sizes are more differ-
ent from each other than what would be expected due
to chance (random error) alone. In meta-analyses using
pre-post SMDs, heterogeneity can be extremely high,
sometimes more than 90% (Johnsen & Friborg, 2015).
This makes the interpretation of the results of these
meta-analyses very uncertain, because the true effect
size in a specific context is likely very different from
the true effect size in another and hence it is impossible
to say under which circumstances a given effect size
could be expected.
Pre-test and post-test scores are not independent
from each other
Another important problem with pre-post SMDs is
that the scores on the outcome measures at pre-test
and those at post-test are not independent of each
other, and the correlation between these two scores
should be accounted for in the calculation of the pre-
post SMDs. The character of this problem is not so
much related to the design of the studies, like the pre-
viously discussed problem of the pre-post SMD, but is
more an improper way of calculating it.
In some meta-analyses the correlation between
pre-test and post-test is just ignored and the SMDs
are calculated as if the pre-test and post-test scores
are independent of each other. Other authors assume
a fixed value for this correlation, because the value
for this correlation is hardly ever reported in trial
reports. The best value to use in such situations
would be the correlation based on existing reports of
correlations. In one report of 811 within-group correl-
ation values the median within-group correlation
across all included 123 studies was r = 0.59 (Balk et al.
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2012). However, many authors use a fixed value that
is not based on any empirical data, for example the
value of r = 0.75 or r = 0.7 is used in many studies
(Hesser et al. 2011; Hofmann et al. 2014; Johnsen &
Friborg, 2015). Furthermore, the empirical value of
the within-group correlation of 0.59 is based on the
average of many questionnaires and this does not
mean that this correlation in a specific study in a spe-
cific meta-analysis takes indeed this specific value. The
value for this correlation can (and probably is) differ-
ent for each instrument in each specific study.
So does this use of a fixed value for this correlation
affect the pooled pre-post SMD in a meta-analysis?
Because this has not been examined empirically, we
decided therefore to examine this in an individual
patient data meta-analysis of 16 randomised controlled
trials directly comparing cognitive behaviour therapy
(CBT) with ADM for adults with major depression.
The details on the identification, inclusion and data
extraction have been reported elsewhere (Cuijpers
et al. 2014b; Weitz et al. 2015; Vittengl et al. 2016). In
these data we could calculate the exact value of the cor-
relation between the outcome measures at pre-test and
post-test in both CBT and ADM, and examine how
much that influenced the outcomes of meta-analyses
compared with the outcomes when standard values
for the correlation are used.
First, we calculated the correlation between pre-test
and post-test for each of the 16 studies (based on com-
pleters in these studies), separately for each of the CBT
and ADM conditions. We did that for the three main
depression measures that were used as outcome in
the 16 studies (Hamilton Depression Rating Scale
(HAM-D; Hamilton, 1960); Beck Depression Inventory
(BDI; Beck et al. 1961); the BDI Second Edition (BDI-II;
Beck et al. 1996). Then we pooled the correlations separ-
ately for each instrument and separately for CBT and
ADM, in a series of meta-analyses. We used the com-
puter program Comprehensive Meta-Analysis (version
3.3.070; Biostat Inc., 2015) to calculate pooled correla-
tions, using a random effects model. The pooled corre-
lations across all studies are given in Table 1. As can be
seen these are considerably smaller than the 0.75 that is
assumed in many meta-analyses using pre-post SMDs,
and the 0.59 that was found as the median correlation
in a systematic review (Balk et al. 2012).
Then we calculated the pre-post SMDs for each
study, separately for CBT and ADM, and for each of
the outcome measures, using two methods: (1) using
the correct correlation between pre-test and post-test
for each study (the best estimate of the true SMD);
(2) using different fixed values for the correlations
between pre and post-test. The results are presented
in Table 2. As can be seen, the differences between
the best estimate SMD and the ones based on fixed
correlations ranged overall from ΔSMD =−0.38 to +
0.07. The largest values for ΔSMD are found when the
difference between the fixed value for the correlation
and the true value is large (r = 0.90 in our case) and
when this difference is small (in our case r = 0.00–0.5)
the ΔSMD is also relatively small. This illustrates that
using fixed values for pre-post correlations can have
considerable impact on the estimations of the pre-post
SMD, especially when the estimate of the correlation
differs much from the true value.
It should also be noted that the correlation between
pre-test and post-test can often be estimated, for
example from change score variances. So it is often
not necessary to use a fixed value for the correlation
between pre-test and post-test, and realistic estimates
of this correlation will result in better estimates of the
pooled effect sizes.
Other problems with the pre-post SMD
Besides the impossibility to differentiate between the
effects of treatment and natural processes and the
unknown impact of the correlation between pre-test
and post-test, there are additional problems with the
pre-post SMD.
In some meta-analyses, pre-post SMDs of open stud-
ies (without a comparison group) are combined with
pre-post SMDs of randomised trials (in which only
the SMD for the treatment group is calculated)
(Johnsen & Friborg, 2015). This is problematic because
patients from open studies typically participate in a
study where they get treatment, while in a randomised
trial they know that it will be chance that decides
whether they get a treatment or not. This means that
the populations in open studies and randomised trials
can differ considerably and it cannot be assumed that
they are comparable enough to be combined into one
meta-analysis.
Table 1. Pooled correlations between pre-test and post-test scores
on the HAM-D, BDI and BDI-II in CBT and ADM for adult
depression
Measure N r 95% CI
CBT HAMD 14 0.18 0.03–0.33
BDI 9 0.20 0.06–0.34
BDI-II 5 0.30 0.11–0.49
ADM HAMD 14 0.19 0.06–0.31
BDI 9 0.24 0.16–0.42
BDI-II 5 0.32 0.11–0.49
CI, confidence interval; CBT, cognitive behavioural therapy;
ADM, anti-depressive medication; HAM-D, Hamilton rating
scale for depression; BDI, Beck’s depression inventory;
BDI-II, BDI second edition.
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In other meta-analyses, pre-post SMDs are calculated
separately for the treatment groups and comparison
groups in randomised trials, and then it is testedwhether
the SMDs from treatment and control groups differ from
each other (e.g., Leichsenring & Rabung, 2008). This
method is also wrong, however, as we explained earlier,
because the pre-post SMDs are still influenced by natural
processes and characteristics of the patients and settings,
in contrast to the between group SMDs.
Discussion
In this paper we described why pre-post SMDs should
be avoided in meta-analyses. The most important rea-
son to avoid pre-post SMDs, however, is that they are
influenced by natural processes and characteristics of
the patients and settings, and these cannot be dis-
cerned from the effects of the intervention. Between
group SMDs are sounder because they control for
such variables. Another important reason why pre-
post SMDs should be avoided is that the scores from
pre- and post-intervention are not independent from
each other. The value for the correlation between
these two time points should be used in the calculation
of the SMD, but this value is typically not known. We
showed that this can lead to considerable errors in the
estimation of the SMDs.
So does this mean that pre-post SMDs should not be
used at all? When the limitations of the pre-post SMDs
are taken into consideration they can be useful in some
cases. For example, in some meta-analyses pre-post
SMDs are used to compare improvement found in
routine practice with improvement found in patients
participating in randomised trials (van der Lem et al.
2012a, b). In other meta-analyses pre-post SMDs are
used to examinewhat happens during natural follow-up
in trials when no control group is available anymore
(Hesseretal. 2011). Suchmeta-analysescanstillbe inform-
ative, despite the disadvantages of the SMDs.
We can conclude that insofar as possible pre-post
SMDs should be avoided, because they can contribute
to biased outcomes and do not give reliable informa-
tion about treatment effects. The results of highly
cited and influential meta-analyses based on the pre-
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Table 2. Pre-post effect sizes based on different values for the correlations between pre-test and post-test
HAMD (N = 14) BDI (N = 9) BDI-II (N = 5)
SMD 95% CI ΔSMD SMD 95% CI ΔSMD SMD 95% CI ΔSMD
True effect size based on exact correlations
CBT 1.79 1.37–2.21 – 1.87 1.44–2.30 – 1.68 1.36–1.99 –
ADM 2.07 1.65––2.49 – 1.87 1.33–2.40 – 1.88 1.20–2.56 –
Fixed values for r
r = 0.90 CBT 1.46 1.13–1.78 −0.33 1.76 1.41–2.12 −0.10 1.41 1.13–1.68 −0.27
ADM 1.69 1.36–2.02 −0.38 1.52 1.10–1.94 −0.35 1.92 1.23–2.61 0.04
r = 0.75 CBT 1.69 1.31–2.07 −0.10 1.91 1.51–2.30 0.04 1.59 1.32–1.86 −0.09
ADM 1.94 1.57–2.31 −0.13 1.75 1.29–2.20 −0.12 1.93 1.23–2.62 0.05
r = 0.50 CBT 1.80 1.39–2.21 0.01 1.94 1.51–2.36 0.07 1.68 1.41–1.95 0.00
ADM 2.04 1.65–2.44 0.03 1.87 1.39–2.34 0.00 1.92 1.22–2.61 0.04
r = 0.25 CBT 1.84 1.41–2.26 0.05 1.93 1.49–2.37 0.06 1.72 1.44–2.00 0.04
ADM 2.07 1.66–2.47 0.00 1.91 1.43–2.39 0.04 1.91 1.21–2.61 0.03
r = 0.00 CBT 1.85 1.41–2.29 0.06 1.92 1.48–2.36 0.05 1.74 1.46–2.02 0.04
ADM 2.07 1.66–2.48 0.00 1.93 1.45–2.42 0.06 1.90 1.20–2.60 0.02
SMD, standardised mean difference; CI, confidence interval; CBT, cognitive behavioural therapy; ADM, anti-depressive medica-
tion; BDI, Beck’s depression inventory; BDI-II, BDI second edition.
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